Top 10 pharmaceutical companies with the largest R & D investment
Last Update: 2020-06-19
Search more information of high quality chemicals, good prices and reliable suppliers, visit
2019 is a good year for new drug developmentThe FDA has approved 48 new molecular entities (NME) in totalAlthough the number is lower than the record 59 NME approved in 2018, the number is still at the top in the past 25 years< br / > < br / > 2019 is also a year for the biomedical industry to actively invest in product research and developmentThe top 10 biomedical companies with the largest R & D investment have invested a total of US $82 billion in the development of innovative drugs, diagnostic methods and vaccines, an increase of US $4 billion over 2018Today, "fierce biotech" released the list of top 10 pharmaceutical companies with the largest R & D investment in 2019The content team of Wuxi apptec will share with readers the latest progress and layout of R & D investment of these large pharmaceutical enterprises< br / >The company's R & D investment this year topped the list, an increase of 6% compared with last year< br / > < br / > < br / > at the end of last year, Roche completed the acquisition of spark therapeutics, a star company of gene therapy, and continued to expand the treatment of hemophiliaAt the same time, the company has reached a large-scale research cooperation with Sarepta company, which shows Roche's determination to expand the field of gene therapy< br / > < br / > oncology has always been the primary area of Roche's R & D investmentRoche, on the one hand, is committed to expanding the scope of application of tecentriq, the company's heavyweight PD-L1 inhibitor, on the other hand, is also developing a new generation of immunocheckpoint inhibitorsBoth efforts have yielded fruitful resultsTecentriq was approved in May this year to be used in combination with Avastin for the first-line treatment of liver cancer patientsTiragolumab, an anti tigit antibody developed by the company, also made a brilliant debut at the recent ASCO annual meetingIt was used in combination with tecentriq in phase 2 clinical trials, showing a promising effect Roche has launched eight clinical trials to further test the potential of tiragolumab in the treatment of multiple cancer types, including two phase 3 trials for non-small cell lung cancer (NSCLC) < br / > < br / > last year, the company's "first in class" antibody coupling drug, poly, and "unlimited cancer species" Trk inhibitor, rozlytrek, were approved by the FDA This year, risdiplam, the company's oral SMN2 gene splicing regulator, may be approved by the FDA to provide an oral therapy for patients with spinal muscular atrophy (SMA) Its IL-6 receptor antibody satralizumab may also be approved by FDA for the treatment of optic neuromyelitis pedigree diseases < br / > Company: Johnson & Johnson < br / > In 2019, spravato, developed by the company, became a new treatment option for patients with resistant depression for decades Moreover, the FGF receptor inhibitor balversa (erdafitinib) has also been approved by FDA to treat specific bladder cancer patients This is the first targeted therapy for such patients < br / > < br / > < br / > in terms of R & D process, the BCMA targeted car-t therapy jnj-4528 jointly developed by Janssen company of Johnson & Johnson and Nanjing legend company has been recognized as a breakthrough therapy by FDA At the recently concluded ASCO annual meeting, jnj-4528 continued to show excellent efficacy in clinical trials of patients with relapsed / refractory multiple myeloma, with a complete remission rate of 86% Janssen has the exclusive right to develop the PARP inhibitor zejula (niraparib) for the treatment of prostate cancer At present, this research and development project is in the phase 3 clinical development stage, and it has also been recognized by FDA as a breakthrough therapy < br / > This innovative therapy has achieved positive results in clinical trials of NSCLC patients with EGFR exon 20 insertion mutation, and is expected to submit regulatory applications by the end of this year < br / > Company: MSD < br / > This partly reflects the company's investment in the blockbuster PD-1 inhibitor keytruda (pembrolizumab) Keytruda's performance did not fail to live up to the investment of mosadon Last year, it was approved to treat non muscle invasive bladder cancer, renal cell cancer, endometrial cancer and first-line treatment of head and neck cancer At this year's ASCO annual meeting, as a single drug or combined with other therapies, it also showed positive effects in the treatment of three negative breast cancer, MSI-H colorectal cancer and other cancer types < br / > < br / > < br / > This will further expand the scope of this heavyweight therapy < br / > < br / > in addition to keytruda, the cooperation between the company and AstraZeneca on the PARP inhibitor lynparza, as well as the cooperation with Weicai on the VEGFR inhibitor lenvima has also yielded fruitful results Lynparza has recently been approved for the treatment of metastatic castrated resistant prostate cancer, and for the first-line maintenance treatment of ovarian cancer patients with mutations in the homologous recombinant repair gene, in combination with Avastin < br / > < br / > in the R & D pipeline, mk-7684, the tigit inhibitor of MSD, is also expected Another cancer therapy worthy of attention is the HIF-2 α inhibitor pt2977, which was acquired last year by mershadong from peloton At this year's ASCO annual meeting, it also obtained positive clinical trial results < br / > The innovative antibiotic recarbrio has also been approved for the treatment of hospital acquired bacterial pneumonia The company's partnership with AstraZeneca also brought koselugo, the first drug to treat type 1 neurofibromatosis < br / > Company: Novartis < br / > < br / > R & D Investment: US $9.4 billion < br / > < br / > R & D investment accounted for 19.8% of the sales volume < br / > Novartis performed very well in the approval of new drugs in 2019, with a total of 6 new drugs approved, including many innovative therapies with great potential For example, zolgensma, a gene therapy for spinal muscular atrophy, piqray for HR + / HER2 breast cancer patients with PIK3CA mutation, and mayzent (siponimod) for multiple sclerosis patients, etc < br / > < br / > < br / > the company's R & D investment in 2019 also increased significantly compared with 2018, with an increase of 13% < br / > < br / > in 2020, tabrecta (capmatinib), the company's met inhibitor, has been approved by FDA as the first approved treatment for NSCLC patients with mutations in exon 14 of met This year, Novartis expects approval for its anti-CD20 antibody, ofatumumab, to treat relapsing multiple sclerosis < br / > This RNAi therapy is expected to be the first to treat a large number of patients with public diseases < br / > Company: Pfizer < br / > Upjohn, the company's generic business unit, also merged with mylan to focus Pfizer itself more on innovation based product development The R & D investment of Pfizer in 2019 is 8% higher than that in 2018 Through the US $11.4 billion acquisition of array biopharma, Pfizer further expanded its oncology research and development pipeline, including the acquisition of braftovi, the BRAF inhibitor Its combination therapy with Erbitux, an EGFR inhibitor, has been approved by the FDA It is a second-line therapy for colorectal cancer patients with specific BRAF mutations < br / > < br / > < br / > Pfizer is also active in the field of gene therapy In the research and development pipeline, the rapid progress in research and development therapy includes fidanacogene elaparvovec for b-hemophilia and sb-525 for a-hemophilia In the treatment of Duchenne muscular dystrophy (DMD), the company's gene therapy will launch three clinical trials in the second half of this year According to < br / > < br / > Pfizer, there may be up to 15 proof of concept studies in 2020, including 5 key clinical trials The company is also likely to launch up to 10 key clinical trials < br / > Company: Sanofi < br / > < br / > R & D Investment: US $6.52 billion < br / > < br / > R & D investment accounts for 16.7% < br / > similar to Pfizer, Sanofi is also a large pharmaceutical enterprise that is changing its corporate framework and focusing on R & D again Under the leadership of Paul Hudson, the new CEO, and Dr John Reed, the global head of R & D, the company not only adjusted the company's structure, but also adjusted the R & D focus of the R & D pipeline At the end of 2019, Sanofi acquired synthorx, a synthetic biology company, for us $2.5 billion During the "capital markets day" activity at the end of the year, Mr Paul Hudson said that he would focus resources on cancer immunotherapy, vaccines, and six key research and development projects in the pipeline centered on dupixent (dupilumab) < br / > < br / > < br / > in 2020, the company's anti-CD38 antibody sarclisa (isatuximab) has been approved by the FDA to treat patients with recurrent multiple myeloma This is Sanofi's first approved new cancer treatment in 10 years < br / > < br / > sar442168, an oral Btk inhibitor in the R & D pipeline, reached the primary end point in phase 2 clinical trials in patients with multiple sclerosis Sanofi plans to launch four phase 3 trials to treat patients with recurrent and progressive multiple sclerosis < br / > < br / > Company: abbvie < br / > < br / > R & D Investment: US $6.41 billion The company's R & D investment, which accounted for 19% of sales last year, has been at the top of the list < br / > < br / > < br / > in the field of blood cancer, the company's Btk inhibitor imbruvica and Bcl-2 inhibitor venclexta are still expanding their scope of application Last year, the company's IL-23 antagonist, skyrizi (risankizumab), was approved for psoriasis and its Jak1 selective inhibitor, rinvoq (uPA acitinib), for rheumatoid arthritis A week ago, the company's oral therapy oriahnn was approved by the FDA to treat patients with moderate menstrual bleeding associated with uterine fibroids < br / > < br / > in the R & D pipeline, the fastest R & D projects include "first in class" Bcl-xL / Bcl-2 inhibitor navitoclax This innovative therapy has achieved positive results in phase 2 clinical trials for the treatment of myelofibrosis It has been approved by the FDA as an orphan drug and is expected to be approved in 2022 < br / > Company: Bristol Myers Squibb (BMS) < br / > < br / > R & D Investment: US $6.15 billion < br / > < br / > R & D investment proportion in sales: 23.6% < br / > Bristol Myers Squibb completed the acquisition of new base company last year It can be expected that in 2020, after integration, the R & D investment of the company will be significantly higher than that in 2019 And the acquisition of Xinji company also gives Baishi
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to email@example.com
. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.